Statera Biopharma is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics derived from naturally occurring lignin. Leveraging a proprietary platform that modifies lignin polymers to create targeted drug conjugates, the company aims to address a range of chronic and acute diseases. Its core pipeline programs include candidates for metabolic disorders, inflammatory conditions and fibrotic diseases, each designed to combine enhanced tissue specificity with favorable safety profiles.
The company’s lignin-based platform enables Statera Biopharma to generate a diverse array of molecular scaffolds that can be conjugated to various small-molecule and biologic payloads. This modular approach not only accelerates lead optimization but also offers the potential for differentiated pharmacokinetic and pharmacodynamic properties. With proof-of-concept studies underway in multiple preclinical models, the platform has demonstrated promising results in delivering therapeutic agents directly to target tissues while minimizing off-target exposure.
Founded in 2019 and headquartered in Durham, North Carolina, Statera Biopharma operates research facilities in the United States and collaborates with academic institutions and contract research organizations to advance its pipeline. The company’s scientific team combines expertise in natural product chemistry, polymer science and pharmacology, and is supported by a leadership group with decades of experience in biotech venture creation, drug development and regulatory strategy.
Serving markets across North America, Europe and Asia through strategic partnerships and licensing arrangements, Statera Biopharma seeks to establish a new class of lignin-based therapeutics that can address unmet medical needs. With an emphasis on sustainable, plant-derived materials and a platform designed for rapid expansion into multiple therapeutic areas, the company is positioned to leverage its novel technology in pursuing long-term growth and value creation for patients and stakeholders alike.
AI Generated. May Contain Errors.
Free STAB Stock Alerts